Compare ABVC & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABVC | SILO |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 4.6M |
| IPO Year | 2009 | 2011 |
| Metric | ABVC | SILO |
|---|---|---|
| Price | $1.04 | $0.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.5K | ★ 181.7K |
| Earning Date | 03-03-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.14 | ★ 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $509,589.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.22 |
| 52 Week High | $4.02 | $1.18 |
| Indicator | ABVC | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 49.34 |
| Support Level | N/A | $0.33 |
| Resistance Level | $1.67 | $0.39 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 29.19 | 49.40 |
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.